(833) 317-6278
Book a Demo
Alex Zhavoronkov
Gray shield icon
Is this you?
Claim your profile.

Alex Zhavoronkov

Founder and CEO

AS SEEN ON
Genetic Engineering & Biotechnology News

Preston's Summary

Alex Zhavoronkov is the Founder and CEO of Insilico Medicine, a company specializing in artificial intelligence for drug discovery and longevity research. He writes for Forbes, covering topics such as longevity biotechnology, AI in drug discovery, and the future of healthcare. His articles provide insights into the latest scientific advancements and their potential impact on the pharmaceutical industry.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

Coverage Attributes:

Beta
Event Coverage: 26 %
Cites Data: 26 %
Industry Specific: 23 %
Expert Commentary: 3 %
Government Announcement: 3 %

Themes Covered:

Most Recent Topics:

  • Deep Learning
  • MLOps

Pitching Insights

Alex Zhavoronkov's coverage primarily focuses on the intersection of technology, healthcare, and pharmaceuticals. His interest in longevity biotechnology, AI in healthcare, drug discovery, and medical breakthroughs suggests a strong emphasis on innovative developments within these fields.

Given the specific nature of his article titles and topics covered, Alex would likely be interested in pitches that offer expert insights into cutting-edge technological advancements or scientific breakthroughs related to longevity biotechnology and artificial intelligence within the healthcare and pharmaceutical sectors.

As he often cites data and covers industry-specific events, potential sources should possess deep knowledge or involvement within these specialized areas to provide credible commentary. Furthermore, given his broad geographic focus (as no specific region is mentioned), globally relevant perspectives are likely to capture his attention.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Steven Levy

Steven Levy

Editor At Large
*****n@*******om
Publications
WIRED, NewsBreak, Tech News Tube, Magzter, theatre-news.com
Most recent topics
Tech, Big Tech, Software & SaaS, Crypto & Blockchain, Culture & Society
Alison Snyder

Alison Snyder

Managing Editor
*****n@*******om
Publications
Axios
Most recent topics
Scientific, Science, Data & Analytics, Engineering, Content & Publishing
Brian Buntz

Brian Buntz

Pharma Editor
*********tz@*********om
Publications
R&D - Research & Development World, Drug Discovery & Development, NewsBreak, productinnovationtimes.com
Most recent topics
Healthcare & Pharmaceutical, Scientific, Data & Analytics, Biotechnology, Finance & Economy
Gil Press

Gil Press

Forbes
Publications
Forbes
Most recent topics
Tech, Healthcare & Pharmaceutical, Business, Science, Business & Industry
Camille Bello

Camille Bello

Journalist - Associate producer
Publications
Euronews
Most recent topics
Scientific, Culture & Society, Healthcare & Pharmaceutical, Tech, Health
Eric Joseph Gomes

Eric Joseph Gomes

Publications
Eduvast
Most recent topics
Content & Publishing, Software & SaaS, Business & Industry, Transportation & Logistics, Product Promotions

Articles

Cell Press

TNIK's emerging role in cancer, metabolism, and age-related diseases

TNIK's emerging role in cancer, metabolism, and age-related diseases

By: Irena Hq, Schwerzenbach Ch, Sarah Wing, Yan Lok, Alex Zhavoronkov, Collin Y. Ewald, Frank W. Pun, Fadi E. Pulous, Alex Aliper

Highlights Recent advances have demonstrated that Traf2- and Nck-interacting kinase (TNIK) is a key regulator of physiological and pathological metabolic signaling during cancer, obesity, and neurodegeneration.

© 2024 Intelligent Relations